Abilify “Dear Doctor” letter
Executive Summary
Bristol-Myers Squibb's March 25 "Dear Doctor" 1letter on the atypical antipsychotic class warning for diabetes says "an exhaustive review of the Abilify database revealed no increased signal for diabetes," although "additional information is needed to confirm this." Bristol and Otsuka updated Abilify (aripiprazole) labeling in March to reflect FDA's requested class warning (2"The Pink Sheet" April 5, 2004, p. 32)...
You may also be interested in...
Bristol Diabetes Class Warning For Abilify Cites “Paucity” Of Reports
Bristol-Myers Squibb's Abilify now carries a diabetes class warning for atypical antipsychotics, although the company plans to continue discussions with FDA about modifications as new data become available
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.